Fabino Enterprises Ltd Stock Price Today (NSE: FABINO)
Fundamental Score
Fabino Enterprises Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Fabino Enterprises Ltd share price today is ₹20.31, up +0.00% on NSE/BSE as of 7 August 2026. Fabino Enterprises Ltd (FABINO) is a Small-cap company in the Pharmaceuticals & Biotechnology sector with a market capitalisation of ₹5.09 (Cr). The 52-week high for FABINO share price is ₹27.00 and the 52-week low is ₹13.01. At a P/E ratio of 84.83x, FABINO is currently trading above its industry average P/E of 33.97x. The company has a Return on Equity (ROE) of 1.44% and a debt-to-equity ratio of 0.43.
Fabino Enterprises Ltd Share Price Chart — NSE/BSE Historical Performance
Fabino Enterprises Ltd share price chart: 0.00% return over the past month. 52-week high ₹27.00, 52-week low ₹13.01.
Fabino Enterprises Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹20.31 | ₹20.31 | ₹20.31 | ₹20.31 | 0.00 (Cr) | |
| ₹20.31 | ₹20.31 | ₹20.31 | ₹20.31 | 0.00 (Cr) | |
| ₹20.31 | ₹20.31 | ₹20.31 | ₹20.31 | 0.00 (Cr) | |
| ₹20.31 | ₹20.31 | ₹20.31 | ₹20.31 | 0.00 (Cr) | |
| ₹20.31 | ₹20.31 | ₹20.31 | ₹20.31 | 0.00 (Cr) | |
| ₹20.31 | ₹20.31 | ₹20.31 | ₹20.31 | 0.00 (Cr) | |
| ₹20.31 | ₹20.31 | ₹20.31 | ₹20.31 | 0.00 (Cr) | |
| ₹20.31 | ₹20.31 | ₹20.31 | ₹20.31 | 0.00 (Cr) | |
| ₹20.31 | ₹20.31 | ₹20.31 | ₹20.31 | 0.00 (Cr) | |
| ₹20.31 | ₹20.31 | ₹20.31 | ₹20.31 | 0.00 (Cr) |
Fabino Enterprises Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹20.31 | ₹20.31 | ₹20.31 | ₹20.31 | +0.00% | |
| ₹20.31 | ₹20.31 | ₹20.31 | ₹20.31 | +0.00% | |
| ₹20.31 | ₹20.31 | ₹20.31 | ₹20.31 | +0.00% | |
| ₹20.31 | ₹20.31 | ₹20.31 | ₹20.31 | +0.00% | |
| ₹15.94 | ₹20.31 | ₹15.94 | ₹20.31 | +27.42% | |
| ₹13.10 | ₹15.43 | ₹13.10 | ₹15.19 | +15.95% | |
| ₹13.77 | ₹14.45 | ₹13.10 | ₹13.10 | -4.87% | |
| ₹20.75 | ₹20.75 | ₹13.01 | ₹13.98 | -32.63% | |
| ₹23.00 | ₹27.00 | ₹15.22 | ₹20.75 | -9.78% | |
| ₹23.00 | ₹23.00 | ₹23.00 | ₹23.00 | +0.00% | |
| ₹24.25 | ₹24.25 | ₹23.00 | ₹23.00 | -5.15% | |
| ₹26.00 | ₹26.00 | ₹24.25 | ₹24.25 | -6.73% |
AI Research Briefing
Powered by Gemini · 2026-08-01
Loss-making micro-cap shell undergoing a promoter takeover with zero fundamental support and extreme liquidity risk.
WHAT'S HAPPENING NOW (last 2-4 weeks)
In July 2026, incoming acquirers R G Family Trust, Sameer Gupta, and Sundeep Gupta completed a mandatory open offer to acquire a 26.0% stake at ₹20 per share (total consideration ₹1.09 Cr) after signing a Share Purchase Agreement to acquire 56.82% from existing promoters at ₹18 per share. The post-offer advertisement filed on July 22, 2026, showed a lukewarm response with only 3,000 public shares tendered. FY26 audited financial results showed total income of ₹22.40 Cr, but operations collapsed into a consolidated net loss of ₹0.56 Cr (down from a profit of ₹0.13 Cr in FY25).
CORE STORY (THE REAL GAME)
This is not a biopharma growth compounder; it is a pure micro-cap takeover shell play. The core distribution and packaging business is negligible, generating losses on ₹22.40 Cr revenue. The real narrative is whether the new acquirers—linked to the Jakson Group ecosystem—use this ₹5.09 Cr market cap vehicle for a capital injection or reverse merger into new business segments.
- Promoter change finalised via open offer concluding July 2026 with R G Family Trust acquiring control.
- FY26 financial results confirmed a full-year net loss of ₹0.56 Cr on revenue of ₹22.40 Cr.
- Lukewarm public participation in open offer with only 3,000 shares tendered as reported on July 22, 2026.
- Official asset injection or line-of-business change announcement by new promoters.
- Board restructuring and appointment of new executive management team.
- Q1 FY27 earnings showing a turnaround from the ₹0.56 Cr net loss recorded in FY26.
- Micro/SME cap market value of ₹5.09 Cr presents severe execution and illiquidity risk.
- Swung into a full-year net loss of ₹0.56 Cr in FY26 despite ₹22.40 Cr top-line revenue.
- Absurd P/E valuation of 84.83x vs industry average of 33.97x with poor ROE of 1.44%.
Zero institutional participation with FII at 0.0% (Δ 0.0%) and DII at 0.0% (Δ 0.0%); promoter holding shifting from 56.82% to potential 82.82% post-takeover.
Indian pharma domestic growth remains stable at 7-9%, but micro-cap packaging traders enjoy no structural benefit from macro PLI incentives.
No commercial order wins found; corporate event limited to ₹1.09 Cr open offer for 26% equity stake.
No: Operations generated a net loss of ₹0.56 Cr for FY26 with historical 5Y FCF unviable.
Entirely dependent on incoming management's ability to inject profitable assets. Without asset injection, the stock faces persistent downside risks.
Primary Thesis Risk
Incoming promoters fail to inject viable business assets, leaving investors trapped in an illiquid loss-making shell.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Fabino Enterprises Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Fabino Enterprises Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of FABINO across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Robust Profit Growth (160.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (67.64%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Balanced Promoter Holding (56.82%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (1.44%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (5.61%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 84.83x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Interest Coverage (2.46x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Fabino Enterprises Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Fabino Enterprises Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Fabino Enterprises LtdFabino Enterpri...Selected✓ FABINO • 543444 | 32/100 | ₹20.31₹20 | ₹5.09₹5.09 | 84.83Average 84.8 Average | 1.44%Poor 1.44% Poor | 5.61%Poor 5.61% Poor | 0.43Excellent 0.4 Excellent | — — | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Fabino Enterprises Ltd PE Ratio History
Historical price-to-earnings ratio for FABINO — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹0.17 | ₹32.90 | 193.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Fabino Enterprises Ltd Quarterly Performance
Latest quarterly metrics for FABINO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
67.64%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
160.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Fabino Enterprises Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for FABINO — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Fabino Enterprises Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Fabino Enterprises Ltd (FABINO) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Fabino Enterprises Ltd
About FABINO (Fabino Enterprises Ltd)
Fabino Enterprises Ltd is a dynamic and multifaceted pharmaceutical company headquartered in India, driven by a commitment to enhance health and well-being. With a diversified appr...oach, FABINO engages in the complete life cycle of pharmaceutical products, from meticulous manufacturing and rigorous quality control to strategic marketing and efficient distribution. Their portfolio encompasses a wide spectrum of allopathic and herbal formulations, addressing numerous therapeutic areas with tablets, syrups, ointments, and more. FABINO prides itself on delivering accessible and reliable healthcare solutions to meet the evolving needs of the Indian population, establishing a reputation for quality and innovation in the pharmaceutical landscape. Beyond pharmaceuticals, FABINO extends its reach into the realm of consumer wellness, offering a range of food and wellness products under its established Fabino and Keepshine brands. These products cater to a growing consumer demand for health-conscious choices, reflecting FABINO's dedication to holistic well-being. Their wellness line spans from nutritional supplements to everyday essentials, all formulated with a focus on quality and efficacy. This strategic diversification into consumer goods allows FABINO to connect with a broader audience, fostering brand loyalty and expanding its market presence beyond the traditional pharmaceutical sector. FABINO Enterprises Ltd also actively participates in the global market through exports, expanding its reach and impact beyond Indian borders. Their export portfolio includes a diverse array of wellness and fast-moving consumer goods (FMCG), encompassing products like coffee, malt powder, protein powder, and hair shampoo. By leveraging its manufacturing capabilities and quality standards, FABINO caters to international demands while solidifying its position as a competitive player in the global market. This international outlook further demonstrates FABINO's commitment to innovation, growth, and contributing to wellness on a global scale.
Company Details
Key Leadership
FABINO Share Price: Frequently Asked Questions
What is the current share price of Fabino Enterprises Ltd?
Fabino Enterprises Ltd (FABINO) trades at ₹20.31 on NSE and BSE. Market cap ₹5.09 (Cr). Educational data only.
What is the P/E ratio of Fabino Enterprises Ltd?
Fabino Enterprises Ltd has a P/E of 84.83x vs industry average 33.97x.
What is the Bull Run score for Fabino Enterprises Ltd?
Fabino Enterprises Ltd has a Bull Run score of 32/100 based on 25+ financial parameters.
Does Fabino Enterprises Ltd pay dividends?
Fabino Enterprises Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Fabino Enterprises Ltd?
Fabino Enterprises Ltd has ROE of 1.44%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Fabino Enterprises Ltd?
Fabino Enterprises Ltd has debt-to-equity of 0.43.
Is Fabino Enterprises Ltd a good investment?
Bull Run gives Fabino Enterprises Ltd a score of 32/100. This is not investment advice — consult a SEBI-registered advisor.